scholarly article | Q13442814 |
P819 | ADS bibcode | 2018NatCo...9.1126G |
P6179 | Dimensions Publication ID | 1101559592 |
P356 | DOI | 10.1038/S41467-018-03512-5 |
P932 | PMC publication ID | 5859133 |
P698 | PubMed publication ID | 29555900 |
P50 | author | Matthias Krause | Q44831846 |
Louis Chesler | Q58398809 | ||
Hadeel Adel Al-Lami | Q59544103 | ||
Evon Poon | Q63376603 | ||
Sandra Guadalupe Gonzalez Malagon | Q90844413 | ||
Karen J. Liu | Q41841535 | ||
P2093 | author name string | Christopher J Phiel | |
Anna M Lopez Muñoz | |||
Daniel Doro | |||
Elizabeth R Tucker | |||
Triòna G Bolger | |||
P2860 | cites work | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells | Q21735929 |
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis | Q24529125 | ||
GSK-3: tricks of the trade for a multi-tasking kinase | Q24624069 | ||
Identification of ALK as a major familial neuroblastoma predisposition gene | Q24655923 | ||
GSK-3-selective inhibitors derived from Tyrian purple indirubins | Q27642879 | ||
Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6 | Q27682291 | ||
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
Activating mutations in ALK provide a therapeutic target in neuroblastoma | Q27851452 | ||
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. | Q27853323 | ||
Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium | Q28269508 | ||
Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics | Q28286512 | ||
Novel reporter alleles of GSK-3α and GSK-3β | Q28485292 | ||
Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity | Q28568803 | ||
The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3 | Q29614380 | ||
Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase | Q29615040 | ||
Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse | Q29620355 | ||
Lamellipodin and the Scar/WAVE complex cooperate to promote cell migration in vivo | Q30557898 | ||
Neural crest induction by Xwnt7B in Xenopus | Q42672853 | ||
Interactions between Twist and other core epithelial-mesenchymal transition factors are controlled by GSK3-mediated phosphorylation. | Q42755971 | ||
Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. | Q43631715 | ||
Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET. | Q44682327 | ||
Inactivation of Cdc42 in neural crest cells causes craniofacial and cardiovascular morphogenesis defects | Q44928146 | ||
The MAP kinase pathway is upstream of the activation of GSK3beta that enables it to phosphorylate MAP1B and contributes to the stimulation of axon growth. | Q45287460 | ||
Ectodermal Wnt function as a neural crest inducer. | Q46043546 | ||
Characterization of the expression of the ALK receptor tyrosine kinase in mice | Q46927486 | ||
Temporal control of neural crest lineage generation by Wnt/β-catenin signaling. | Q51785160 | ||
Chemical rescue of cleft palate and midline defects in conditional GSK-3beta mice. | Q51994753 | ||
Overexpression of Xgsk-3 disrupts anterior ectodermal patterning in Xenopus. | Q52201903 | ||
Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. | Q54633263 | ||
Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3 | Q72164616 | ||
Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts | Q73958600 | ||
In silico studies of potential phosphoresidues in the human nucleophosmin/B23: its kinases and related biological processes | Q84099764 | ||
Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion | Q86636596 | ||
GSK3 and Polo-like kinase regulate ADAM13 function during cranial neural crest cell migration | Q30607535 | ||
Regulation of dorsal fate in the neuraxis by Wnt-1 and Wnt-3a | Q33721756 | ||
Neural crest cell-specific deletion of Rac1 results in defective cell-matrix interactions and severe craniofacial and cardiovascular malformations | Q33788024 | ||
Dissection of Xenopus laevis neural crest for in vitro explant culture or in vivo transplantation | Q34009403 | ||
Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo | Q34179931 | ||
GSK3 takes centre stage more than 20 years after its discovery | Q34374129 | ||
NEURODEVELOPMENT. Shared regulatory programs suggest retention of blastula-stage potential in neural crest cells | Q34474556 | ||
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
Contact inhibition of locomotion in vivo controls neural crest directional migration | Q34902880 | ||
What Are the bona fide GSK3 Substrates? | Q35001234 | ||
Polarized regulation of glycogen synthase kinase-3β is important for glioma cell invasion | Q35061356 | ||
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | Q35575978 | ||
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma | Q36160258 | ||
Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. | Q36257802 | ||
A stable cranial neural crest cell line from mouse | Q36390173 | ||
Delamination of neural crest cells requires transient and reversible Wnt inhibition mediated by Dact1/2 | Q37036244 | ||
Glycogen synthase kinase 3 in the world of cell migration | Q37627916 | ||
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo | Q37718461 | ||
The connections between neural crest development and neuroblastoma | Q37836006 | ||
Rho family GTPases | Q38061989 | ||
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. | Q38130615 | ||
Glycogen synthase kinase-3beta phosphorylation of MAP1B at Ser1260 and Thr1265 is spatially restricted to growing axons. | Q38330149 | ||
Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic | Q38540135 | ||
GSK3 inhibitors in the therapeutic development of diabetes, cancer and Neurodegeneration: Past, present and future | Q38656644 | ||
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells | Q39367969 | ||
Primary culture of chick, mouse or human neural crest cells | Q39465676 | ||
Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration | Q39498392 | ||
Controlled levels of canonical Wnt signaling are required for neural crest migration | Q39657006 | ||
Oncogenic mutations of ALK kinase in neuroblastoma | Q39928776 | ||
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma | Q39928780 | ||
FAK phosphorylation at Ser-843 inhibits Tyr-397 phosphorylation, cell spreading and migration. | Q40209895 | ||
Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation | Q40872093 | ||
MYCN induces neuroblastoma in primary neural crest cells. | Q41599713 | ||
Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS. | Q41688422 | ||
An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. | Q41810461 | ||
Reprogramming of avian neural crest axial identity and cell fate | Q42372116 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1126 | |
P577 | publication date | 2018-03-19 | |
P1433 | published in | Nature Communications | Q573880 |
P1476 | title | Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. | |
P478 | volume | 9 |
Q54977695 | 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. |
Q58786649 | ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells |
Q64117777 | BMP4 and Neuregulin regulate the direction of mouse neural crest cell differentiation |
Q91891632 | Integrating chemical and mechanical signals in neural crest cell migration |
Q95293828 | Modulation of β-catenin levels regulates cranial neural crest patterning and dispersal into first pharyngeal arch |
Q58585886 | Rosmarinic Acid Derivatives' Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer's Disease |
Q91811171 | The Many Faces of Xenopus: Xenopus laevis as a Model System to Study Wolf-Hirschhorn Syndrome |
Search more.